Ferro Pharma is a facilitator in the pharmaceutical industry with the goal to disrupt existing value chains. We make new and innovative pharmaceutical intermediates, active pharmaceutical ingredients (APIs) from China and finished dosage forms (FDFs) as well as biologics from Europe available to customers around the globe.

Our FDFs are available immediately for customers including a European CTD Format Dossier (containing all five modules required by the European Medicine Authority (EMA)). The manufacturing site in Europe is a fixed asset of our deals. Technical Transfers are possible in selected cases and after the expiry of an agreed delivery obligation. Ferro Pharma is specialized in package deals with customers aiming at an immediate enlargement of their portfolio of drugs marketed. We do not ask for down payments to fertilize our approach of Making Latest Medicines Available (EMELEMA®).

Always with a strategic focus, and supported by our holding company CARELA HOLDING, we are constantly seeking investment opportunities into second and later stage health services and medicine technology. This way we have materialized two investments within the last two years in China and Switzerland in both branded healthcare products and an innovative drug delivery technology.


Sourcing of Intermediates for Innovators

We provide intermediates for science driven companies. Our office in China is among the best-established sourcing and procurement offices in the country, with a team of former employees of the SFDA, as well as well-trained staff with educational backgrounds in Biochemistry, Chemistry and business management.

Sourcing and sales of generic APIs

We provide Active Pharmaceutical Ingredients (APIs) for customers in Latin America and Europe, who are developing latest generic formulations (FDF). With our offices in China, Germany and Malta we offer a hub for them to identify and qualify the right manufacturer. Ferro Pharma also trains the supplier in all aspects of quality and regulatory means, which are required by ANVISA, COFEPRIS, INVIMA, DIGEMID, UNIMED, ANAMED and EMA.

Licensing-out of EU generics

We license-out finished Dosage Forms (FDFs), manufactured and registered in Europe to customers in China, Brazil, Mexico, Peru, Bolivia, Chile, Ecuador and Colombia. In this segment, Ferro Pharma cuts value chains by offering existing EMA-approved dossiers to customers, ideally as a package of several products out of one hand. Thus, customers can efficiently plan their internal resources to file several drugs for registration at once.

Investment into Innovative technologies

Ferro Pharma invests into and takes over active distribution management of technologies with a focus on novel means of drug delivery and digital health. In this way, existing customers can expand their product scope locally via these technologies. By May 2018 we have already materialized participating in a new line of oncology drug delivery, a new oral drug delivery system, an innovative technology in the inflammatory diseases sector and we have substantially invested into a distribution platform for health products in China.